Lin, Donna Shu-HanDonna Shu-HanLinJEN-KUANG LEEWEN-JONE CHEN2021-11-012021-11-012021-090012186Xhttps://scholars.lib.ntu.edu.tw/handle/123456789/586034The safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP1RAs) and dipeptidyl peptidase-4 inhibitors (DPP4is) in major cardiovascular adverse events were previously examined in cardiovascular outcome trials. However, the effects of these drugs on adverse limb outcomes were poorly examined. This study aimed to determine the real-world outcomes of patients with diabetes mellitus receiving GLP1RAs as compared with those receiving DPP4is in terms of major adverse cardiovascular and limb events.enDiabetes; Dipeptidyl peptidase-4 inhibitors; Glucagon-like peptide-1 receptor agonist; Major adverse cardiovascular events; Major adverse limb events[SDGs]SDG32,4 thiazolidinedione derivative; acetylsalicylic acid; alpha glucosidase inhibitor; anticoagulant agent; antidiabetic agent; beta adrenergic receptor blocking agent; calcium channel blocking agent; cilostazol; clopidogrel; cyclooxygenase 2 inhibitor; digjournal article10.1007/s00125-021-05497-1341958652-s2.0-85114056406https://api.elsevier.com/content/abstract/scopus_id/85114056406